Farydak

Refractory Multiple Myeloma
Treatment
1 FDA approval
20 Active Studies for Farydak

What is Farydak

PanobinostatThe Generic name of this drug
Treatment SummaryPanobinostat is a medication used to treat multiple myeloma, a cancer of the bone marrow, and is sold under the brand name Farydak. This treatment works by blocking an enzyme that is involved in regulating gene expression. It is approved by the FDA, although additional clinical trials are still in progress to confirm its efficacy. Panobinostat is the most powerful histone deacetylase inhibitor available.
Farydakis the brand name
image of different drug pills on a surface
Farydak Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Farydak
Panobinostat
2015
6

Approved as Treatment by the FDA

Panobinostat, also called Farydak, is approved by the FDA for 1 uses such as Refractory Multiple Myeloma .
Refractory Multiple Myeloma
Used to treat Refractory Multiple Myeloma in combination with Bortezomib

Effectiveness

How Farydak works in the bodyPanobinostat is a drug that helps fight multiple myeloma. It does this by inhibiting a group of proteins called deacetylase or histone deacetylase proteins, which are responsible for regulating how other proteins work. Panobinostat prevents these proteins from doing their job, which has the effect of altering gene expression and inhibiting protein metabolism. It also works in combination with another drug called bortezomib to make the treatment of multiple myeloma more effective.

When to interrupt dosage

The suggested dose of Farydak is contingent upon the recognized affliction. The amount of dosage shifts as per the approach of delivery (e.g. Capsule - Oral or Oral) featured in the table beneath.
Condition
Dosage
Administration
Refractory Multiple Myeloma
, 10.0 mg, 15.0 mg, 20.0 mg
, Oral, Capsule, Capsule - Oral

Warnings

There are 20 known major drug interactions with Farydak.
Common Farydak Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Panobinostat is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Panobinostat is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Panobinostat is combined with Acteoside.
Anagrelide
Major
The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Anagrelide.
Antilymphocyte immunoglobulin (horse)
Major
The risk or severity of adverse effects can be increased when Panobinostat is combined with Antilymphocyte immunoglobulin (horse).
Farydak Toxicity & Overdose RiskFarydak has a warning label that alerts patients and healthcare professionals to the possibility of severe diarrhea and dangerous heart conditions, such as irregular heartbeat and changes in the electrical signals of the heart. To reduce the risk of these side effects, Farydak is accompanied by a Risk Evaluation and Mitigation Strategy (REMS) which includes information about the risks and how to minimize them.
image of a doctor in a lab doing drug, clinical research

Farydak Novel Uses: Which Conditions Have a Clinical Trial Featuring Farydak?

17 active clinical trials are currently underway to assess the efficacy of Farydak in treating Refractory Multiple Myeloma.
Condition
Clinical Trials
Trial Phases
Refractory Multiple Myeloma
52 Actively Recruiting
Phase 3, Phase 1, Phase 2, Not Applicable

Farydak Reviews: What are patients saying about Farydak?

1Patient Review
5/11/2017
Farydak for Multiple Myeloma
DO NOT USE!!! This will damage your liver! My mom was healthy before she took this for one week, and now we're bury her two weeks later.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about farydak

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Farydak discontinued?

"On November 30, 2021, Secura Bio announced the withdrawal of Farydak. The required post-approval studies had not been completed and the clinical benefits of Farydak could not be confirmed at that time."

Answered by AI

What is Farydak used for?

"Farydak is a medication used to treat multiple myeloma. It is used in combination with bortezomib and dexamethasone, and is only indicated for use in patients who have received at least two prior treatments, including bortezomib and an immunomodulatory agent."

Answered by AI

Who manufactures Farydak?

"The Novartis Corporation has been given the go-ahead by the U.S. Food and Drug Administration to start selling Farydak, its new medication for treating patients with multiple myeloma. This is the first time that such a drug, known as an HDAC inhibitor, has been approved for use in the United States."

Answered by AI

Why was Farydak withdrawn?

"The company has decided to withdraw its application because it is not able to finish the clinical studies that were required for the accelerated approval process. Therefore, it has not been able to confirm the clinical benefits of Farydak."

Answered by AI

Clinical Trials for Farydak

Have you considered Farydak clinical trials? We made a collection of clinical trials featuring Farydak, we think they might fit your search criteria.
Have you considered Farydak clinical trials? We made a collection of clinical trials featuring Farydak, we think they might fit your search criteria.
Have you considered Farydak clinical trials? We made a collection of clinical trials featuring Farydak, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top